Folate Receptor–Specific Antitumor Activity of EC131, a Folate-Maytansinoid Conjugate

Abstract

EC131, a new folate receptor (FR)-targeted drug conjugate, was prepared by covalently attaching the vitamin folic acid (FA) to a potent microtubule-inhibiting agent, maytansinoid DM1, via an intramolecular disulfide bond. When tested on cells in culture, EC131 was found to retain high affinity for FRpositive cells and to provide FR-specific cytotoxicity with an IC 50 in the low nanomolar range. The activity of EC131 was completely blocked in the presence of an excess of free FA, and no activity was detected against FR-negative cells. When evaluated against s.c. FR-positive M109 tumors in BALB/c mice, EC131 showed marked antitumor efficacy. Furthermore, this therapeutic effect occurred in the apparent absence of weight loss or noticeable organ tissue degeneration. In contrast, no significant antitumor activity was observed in EC131-treated animals that were codosed with an excess of FA, thus demonstrating the targeted specificity of the in vivo activity. EC131 also showed marked antitumor activity against FR-positive human KB tumors, but not against FR-negative A549 tumors, in nude mice with no evidence of systemic toxicity during or after the therapy. In contrast, therapy with the free maytansinoid drug (in the form of DM1-S-Me) proved not to be effective against the KB model when administered at its maximum tolerated dose (MTD). Taken together, these results indicate that EC131 is a highly potent agent capable of producing therapeutic benefit in murine tumor models at sub-MTD levels. [Cancer Res 2007;67(13):6376-82]

Structures of human folate receptors reveal biological trafficking states and diversity in folate and antifolate recognition

“…The binding mode for folate in state II rationalizes the linkage position for nearly all folate-conjugates, as the cargo for these multifunctional molecules are almost exclusively coupled at or near the γ-carboxylate of the glutamate (28,(48)(49)(50)64). The apohFR state III model highlights dramatic structural changes that occur in hFRs as a result of changes in pH.…”

Promising Prospects for 44Sc-/47Sc-Based Theragnostics: Application of 47Sc for Radionuclide Tumor Therapy in Mice

“…The relative body weight (RBW) was defined as [BW x / BW 0 ], where BW x is the body weight in grams at a given time x and BW 0 the body weight at day 0. The tumor volume was determined by measuring 2 dimensions with a digital caliper and calculated according to the equation [0.5 · (L · W 2 )], where L is the longest axis and W the axis perpendicular to L in millimeters (19). The relative tumor volume (RTV) was defined as [TV x /TV 0 ], where TV x is the tumor volume in mm 3 at a given time x and TV 0 the tumor volume at day 0.…”

Rational Combination Therapy of Vintafolide (EC145) with Commonly Used Chemotherapeutic Drugs

“…As a result, "folate targeting" has been successfully applied toward the delivery of a wide variety of therapeutic-and imaging-based agents to tumors that express the FR protein (9)(10)(11)(12). Compared with their nontargeted counterparts, folic acid-bearing drugs and delivery systems have repeatedly shown greater cancer cell specificity and selectivity in numerous preclinical studies (13)(14)(15)(16)(17)(18)(19)(20). Hence, this targeting strategy leads to improvements in the safety and efficacy of anticancer agents, resulting in an increased therapeutic advantage.…”